{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:23:57Z","timestamp":1767925437968,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BioMed Research International"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p><jats:italic>Objective<\/jats:italic>. This study was conducted to compare the efficacy of standard therapy (radiotherapy\/RT\/CT) with that of antiepidermal growth factor receptor (anti\u2010EGFR) monoclonal antibody (NPC) therapy in patients with advanced nasopharyngeal cancer. <jats:italic>Methods<\/jats:italic>. A meta\u2010analysis was performed to meet the objective of this study. The English databases PubMed, Cochrane Library, and Web of Science were searched. The literature review compared anti\u2010EGFR\u2010targeted therapy with conventional therapy practices. The main outcome measure was overall survival (OS). Secondary goals were progression\u2010free survival (PFS), locoregional recurrence\u2010free survival (LRRFS), distant metastasis\u2010free survival (DMFS), and adverse events (grade 3). <jats:italic>Results<\/jats:italic>. The database search resulted in 11 studies, with a total of 4219 participants. It was found that combining an anti\u2010EGFR regimen with conventional therapy did not enhance OS (hazard\u2009ratio\u2009[HR] = 1.18; 95<jats:italic>%<\/jats:italic>confidence\u2009interval\u2009[CI] = 0.51\u20132.40; <jats:italic>p<\/jats:italic> = 0.70) or PFS appreciably (HR = 0.95; 95<jats:italic>%<\/jats:italic>CI = 0.51\u20131.48; <jats:italic>p<\/jats:italic> = 0.88) in patients with nasopharyngeal carcinoma. While LRRFS increased considerably (HR = 0.70; 95<jats:italic>%<\/jats:italic>CI = 0.67\u20131.00; <jats:italic>p<\/jats:italic> = 0.01), the combined regimen did not improve DMFS (HR = 0.86; 95<jats:italic>%<\/jats:italic>CI = 0.61\u20131.12; <jats:italic>p<\/jats:italic> = 0.36). Treatment\u2010related adverse events included haematological toxicity (RR = 0.2; 95<jats:italic>%<\/jats:italic>CI = 0.08\u20130.45; <jats:italic>p<\/jats:italic> = 0.01), cutaneous reactions (RR = 7.05; 95<jats:italic>%<\/jats:italic>CI = 2.15\u201323.09; <jats:italic>p<\/jats:italic> = 0.01), and mucositis (RR = 1.96; 95<jats:italic>%<\/jats:italic>CI = 1.58\u20132.09; <jats:italic>p<\/jats:italic> = 0.01). <jats:italic>Conclusions<\/jats:italic>. Individuals who have nasopharyngeal cancer do not have an increased chance of surviving until a local recurrence of their disease if they get normal therapy in addition to an anti\u2010EGFR regimen. However, this combination does not enhance overall survival. On the other hand, this factor adds to an increase in the number of adverse effects.<\/jats:p>","DOI":"10.1155\/2023\/9477442","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T22:35:05Z","timestamp":1675722905000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["[Retracted] Treatment Protocols in the Efficacy and Safety of Anti\u2010EGFR Medicines in Combination with Standard Therapy for Patients with Nasopharyngeal Cancer: A Meta\u2010Analysis"],"prefix":"10.1155","volume":"2023","author":[{"given":"Yakun","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6893-9642","authenticated-orcid":false,"given":"Chao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"e_1_2_8_1_2","doi-asserted-by":"publisher","DOI":"10.1177\/1073274821989301"},{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-1702"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32656"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20190244"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30956-0"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1959371"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-22254-3_2"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5615303"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026620666200303123102"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.10.030"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9687-8"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.7417\/CT.2021.2327"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.003"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1201339"},{"key":"e_1_2_8_15_2","first-page":"930","article-title":"Phase II clinical trial of h-R3 combined with radiotherapy in locally advanced nasopharyngeal carcinoma","volume":"19","author":"Wu R. R.","year":"2014","journal-title":"Journal of BUON"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2018.03.002"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.19710"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/coa.13340"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1220374"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13589"},{"key":"e_1_2_8_21_2","first-page":"197","article-title":"Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma","volume":"29","author":"Huang X. D.","year":"2007","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6156-5"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2974-x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5006151"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2017.02.026"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3552-6"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30819"}],"updated-by":[{"DOI":"10.1155\/2023\/9830710","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"record-id":"62319"},{"DOI":"10.1155\/2023\/9830710","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000}}],"container-title":["BioMed Research International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2023\/9477442.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2023\/9477442.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2023\/9477442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T23:33:19Z","timestamp":1722900799000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2023\/9477442"}},"subtitle":[],"editor":[{"given":"Dinesh","family":"Rokaya","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1155\/2023\/9477442"],"URL":"https:\/\/doi.org\/10.1155\/2023\/9477442","archive":["Portico"],"relation":{"retraction":[{"id-type":"doi","id":"10.1155\/2023\/9830710","asserted-by":"object"}]},"ISSN":["2314-6133","2314-6141"],"issn-type":[{"value":"2314-6133","type":"print"},{"value":"2314-6141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"9477442"}}